You are here

breast cancer

Google Health licenses breast cancer detection AI to iCAD

Medtech Dive

Tue, 11/29/22 - 10:58 am

artificial intelligence

The problem with Her2-low testing

EP Vantage

Mon, 11/28/22 - 07:34 pm

HER2-low breast cancer

Pfizer's $1B protein degradation bet yields 3% response rate in Arvinas' midphase breast cancer trial

Fierce Biotech

Tue, 11/22/22 - 11:00 am

protein degradation

clinical trials

Pfizer discards eczema, NASH and breast cancer programs in early-phase clean-out

Fierce Biotech

Tue, 11/1/22 - 12:09 pm

Daiichi Sankyo sets new highs for AstraZeneca-partnered cancer drug Enhertu

Endpoints

Mon, 10/31/22 - 04:15 pm

non-small cell lung cancer

Anixa begins Phase Ib trial of breast cancer vaccine

Clinical Trials Arena

Thu, 10/27/22 - 10:50 am

Anixa Biosciences

clinical trials

AstraZeneca beats Roche twice in a day

EP Vantage

Wed, 10/26/22 - 10:20 am

After a rocky few months, Gilead's Trodelvy keeps recent winning streak rolling with priority review

Fierce Pharma

Tue, 10/11/22 - 04:08 pm

Gilead Sciences

priority review

To prevent unnecessary biopsies, scientists train an AI model to predict breast cancer risk from MRI scans

Stat

Mon, 10/3/22 - 10:05 am

artificial intelligence

Olema Oncology previews Phase III trial plans for dual-mechanism SERD in breast cancer

Clinical Trials Arena

Fri, 09/23/22 - 10:57 am

ESMO: Gilead's Trodelvy makes surprise comeback with above-par breast cancer survival showing

Fierce Pharma

Wed, 09/7/22 - 11:59 pm

Gilead Sciences

HR-positive HER-negative breast cancer

Dizal reports positive Phase I data for breast cancer therapy

Clinical Trials Arena

Tue, 09/6/22 - 10:37 am

Dizal Pharmaceutical

clinical trials

HER2-positive metastatic breast cancer

As Sanofi's SERD falls, Menarini’s advances with EU review

Fierce Biotech

Fri, 08/19/22 - 10:42 am

Sanofi scraps oral SERD strategy after 2nd failure in breast cancer

Fierce Biotech

Wed, 08/17/22 - 10:50 am

clinical trials

FDA approves AstraZeneca, Daiichi drug in breast cancer first

BioPharma Dive

Sun, 08/7/22 - 11:24 pm

HER2-low breast cancer

AstraZeneca wins two recommendations, one priority review

Morningstar

Mon, 07/25/22 - 10:54 am

CytomX slashes headcount by 40% after breast cancer setback, with later-stage development bearing the brunt

Fierce Biotech

Thu, 07/14/22 - 10:58 am

CytomX Therapeutics

praluzatamab ravtansine

The Cytomx paradox

EP Vantage

Mon, 07/11/22 - 10:21 am

CytomX halts lead program and will seek a partner as breast cancer drug disappoints

Endpoints

Thu, 07/7/22 - 10:26 am

clinical trials

praluzatamab ravtansine

This Cancer Drug's News Could Mean Another Blockbuster for AstraZeneca

Motley Fool

Tue, 06/14/22 - 11:42 am

Pages